FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Plastikon Healthcare Guaifenesin And Dextromethorphan 200-20 Recall

GUAIFENESIN AND DEXTROMETHORPHAN 200-20 mg/10 mL, 10 mL cup, packaged in 10 cups per tr…

Plastikon Healthcare LLC · Lawrence, KS

Risk level
Class II
Reported by FDA
Sep 14, 2022
Recall ID
D-1491-2022
Check your lot numberHow we source this data

Summary

Plastikon Healthcare recalled Guaifenesin And Dextromethorphan 200-20 starting Jun 7, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1491-2022 on Sep 14, 2022. Reason: CGMP Deviations: products manufactured under conditions which reflect manufacturing processes that were not adequately controlled. Status: Terminated.

Why it was recalled

CGMP Deviations: products manufactured under conditions which reflect manufacturing processes that were not adequately controlled.

Product description

GUAIFENESIN AND DEXTROMETHORPHAN 200-20 mg/10 mL, 10 mL cup, packaged in 10 cups per tray, 10 trays per carton, For Institutional Use Only, Major Pharmaceuticals, 17177 N Laurel Park Dr. Suite 233, Livonia, MI 48152, NDC 0904-6980-72

Lot numbers, UPCs & expiration codes

Lot # 20091A, EXP Sep. 2022; 20104A, EXP Nov. 2022; 21017A, EXP Feb. 2023; 21034A, 21036A EXP Mar. 2023; 21092A, EXP Aug. 2023; 21105A, 21106A, EXP Oct. 2023; 21134A, EXP Dec. 2023; 22007B, EXP Jan. 2024; 22012A, EXP Feb. 2024; 22016B, EXP Mar. 2024

Where it was sold

Distributed Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1491-2022
Classification
Class II
Status
Terminated
Recall initiated
Jun 7, 2022
FDA report date
Sep 14, 2022
Quantity
246,200 cups
Recall type
Voluntary: Firm initiated
Recalling firm
Plastikon Healthcare LLC

Original FDA data

Every field from FDA enforcement report D-1491-2022, exactly as published.

Show all FDA fields
City
Lawrence
State
KS
Status
Terminated
Country
United States
Event ID
90398
Address
3780 Greenway Cir
Code information
Lot # 20091A, EXP Sep. 2022; 20104A, EXP Nov. 2022; 21017A, EXP Feb. 2023; 21034A, 21036A EXP Mar. 2023; 21092A, EXP Aug. 2023; 21105A, 21106A, EXP Oct. 2023; 21134A, EXP Dec. 2023; 22007B, EXP Jan. 2024; 22012A, EXP Feb. 2024; 22016B, EXP Mar. 2024
Postal code
66046-5440
Report date
Sep 14, 2022
Product type
Drugs
Recall number
D-1491-2022
Classification
Class II
Recalling firm
Plastikon Healthcare LLC
Product quantity
246,200 cups
Termination date
Jun 25, 2025
Reason for recall
CGMP Deviations: products manufactured under conditions which reflect manufacturing processes that were not adequately controlled.
Voluntary / mandated
Voluntary: Firm initiated
Product description
GUAIFENESIN AND DEXTROMETHORPHAN 200-20 mg/10 mL, 10 mL cup, packaged in 10 cups per tray, 10 trays per carton, For Institutional Use Only, Major Pharmaceuticals, 17177 N Laurel Park Dr. Suite 233, Livonia, MI 48152, NDC 0904-6980-72
Distribution pattern
Distributed Nationwide in the USA
Recall initiation date
Jun 7, 2022
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Sep 6, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1491-2022, published Sep 14, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls